These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 35609769

  • 1. JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN).
    Glück M, Dally L, Jücker M, Ehm P.
    Int J Biochem Cell Biol; 2022 Aug; 149():106229. PubMed ID: 35609769
    [Abstract] [Full Text] [Related]

  • 2. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
    Baran-Marszak F, Magdoud H, Desterke C, Alvarado A, Roger C, Harel S, Mazoyer E, Cassinat B, Chevret S, Tonetti C, Giraudier S, Fenaux P, Cymbalista F, Varin-Blank N, Le Bousse-Kerdilès MC, Kiladjian JJ, Velazquez L.
    Blood; 2010 Dec 23; 116(26):5961-71. PubMed ID: 20870899
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
    Marty C, Lacout C, Droin N, Le Couédic JP, Ribrag V, Solary E, Vainchenker W, Villeval JL, Plo I.
    Leukemia; 2013 Nov 23; 27(11):2187-95. PubMed ID: 23558526
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.
    Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, McGuirk J, Bhalla KN.
    Mol Cancer Ther; 2013 May 23; 12(5):577-88. PubMed ID: 23445613
    [Abstract] [Full Text] [Related]

  • 11. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
    Fiskus W, Verstovsek S, Manshouri T, Rao R, Balusu R, Venkannagari S, Rao NN, Ha K, Smith JE, Hembruff SL, Abhyankar S, McGuirk J, Bhalla KN.
    Clin Cancer Res; 2011 Dec 01; 17(23):7347-58. PubMed ID: 21976548
    [Abstract] [Full Text] [Related]

  • 12. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
    Kamishimoto J, Tago K, Kasahara T, Funakoshi-Tago M.
    Cell Signal; 2011 May 01; 23(5):849-56. PubMed ID: 21255641
    [Abstract] [Full Text] [Related]

  • 13. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.
    Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R.
    Sci Transl Med; 2018 Feb 21; 10(429):. PubMed ID: 29467301
    [Abstract] [Full Text] [Related]

  • 14. JAK2V617F-dependent down regulation of SHP-1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF-β.
    Aoun C, Maslah N, Ganesan S, Salomao N, Gendron R, Awan Toor S, Letort G, Gou P, Bonnamy M, Parietti V, Kiladjian JJ, Giraudier S, Cassinat B.
    J Cell Mol Med; 2024 Oct 21; 28(20):e70138. PubMed ID: 39431551
    [Abstract] [Full Text] [Related]

  • 15. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
    Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Dirnhofer S, Guglielmelli P, Vannucchi AM, Feenstra JD, Kralovics R, Orkin SH, Skoda RC.
    J Exp Med; 2016 Jul 25; 213(8):1479-96. PubMed ID: 27401344
    [Abstract] [Full Text] [Related]

  • 16. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.
    FASEB J; 2012 Feb 25; 26(2):894-906. PubMed ID: 22051730
    [Abstract] [Full Text] [Related]

  • 17. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells.
    Machado-Neto JA, Coelho-Silva JL, Santos FPS, Scheucher PS, Campregher PV, Hamerschlak N, Rego EM, Traina F.
    Invest New Drugs; 2020 Jun 25; 38(3):733-745. PubMed ID: 31286322
    [Abstract] [Full Text] [Related]

  • 18. JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
    Irino T, Uemura M, Yamane H, Umemura S, Utsumi T, Kakazu N, Shirakawa T, Ito M, Suzuki T, Kinoshita K.
    PLoS One; 2011 Jun 25; 6(7):e22148. PubMed ID: 21789226
    [Abstract] [Full Text] [Related]

  • 19. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
    Toyama K, Karasawa M, Yokohama A, Mitsui T, Uchiumi H, Saitoh T, Handa H, Murakami H, Nojima Y, Tsukamoto N.
    Intern Med; 2011 Jun 25; 50(21):2557-61. PubMed ID: 22041356
    [Abstract] [Full Text] [Related]

  • 20. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
    Bartalucci N, Guglielmelli P, Vannucchi AM.
    Clin Lymphoma Myeloma Leuk; 2013 Sep 25; 13 Suppl 2():S307-9. PubMed ID: 24290217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.